ProCE Banner Activity

Podcast Pearls: Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

Multimedia
PDF
Download this short summary of key takeaways from a podcast on combination approaches to expand the benefit of PARP inhibitors in prostate cancer.

Released: June 30, 2021

Expiration: June 29, 2022

No longer available for credit.

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Wassim Abida

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Program Director Disclosure

Program Director

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Faculty Disclosure

Primary Author

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain